Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research



Rating:

Share or cite this content

Citations should be made in the following way:
H. Jang (Seoul, Republic of Korea), S. Yong (Seoul, Republic of Korea), E. Kim (Seoul, Republic of Korea), J. Jung (Seoul, Republic of Korea), Y. Kang (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea). Microbial analysis in lung cancer according to PD-L1 level and immunotherapy response. 1128

Member's Comments

No comment yet.

Related content which might interest you: Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis Source: ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019 Year: 2019 The role of CD40 molecule in human lung cancer and its application in immunotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003 Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center. Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 How to evaluate the immune status of lung cancer patients before immunotherapy Source: Breathe, 13 (4) 291; 10.1183/20734735.001917 Year: 2017 Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Gene expression profiling in non-small cell lung cancer (NSCLC) according to smoking status Source: Annual Congress 2008 - Discovery of novel targets in lung disease by means of functional genomics Year: 2008 The expression and biological significance of PD-L1 on lung cancer cell lines Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Different expression of miRNA in non-small cell lung cancer according to its clinical stage Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 1762-1772 Year: 2015 Evaluation expression of miR-146a and miR-155 and inflammatory  cytokines in blood of non-small cell lung cancer patients Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 CAR T-cell therapy for lung cancer Source: International Congress 2017 – A novel approach to lung cancer Year: 2017 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Association of antiPD1 immunotherapy with immunogenic cell death-inducing chemotherapy in a murine model of squamous cell lung cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 The clinical significance of CD40 molecule expressed on human lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003 Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 LSC Abstract – Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016